CCL2 and neoplasm: Another genomic approach revealed that the loss of heterozygosity (LOH) at 17q11.2 increased the cumulative relapse-free survival and cumulative overall survival of cervical cancer patients that were lacking tumor cell-associated CCL2 mRNA, suggesting that the tumor-associated macrophages support tumor progression [31].